Top

Clinical Pharmacokinetics

Published in:

01-04-2012 | Systematic Review

Effect of Molecular Weight and Substitution on Tissue Uptake of Hydroxyethyl Starch

A Meta-Analysis of Clinical Studies

Authors: Romuald Bellmann, Clemens Feistritzer, Professor Christian J. Wiedermann

Published in: Clinical Pharmacokinetics | Issue 4/2012

Abstract

Background

Intravenously infused hydroxyethyl starch (HES) can be found in urine, plasma and tissues. HES remaining in plasma and tissues is thought to increase the risk of clinical complications. HES solutions of lower molecular weight and substitution have been developed to increase urinary excretion and reduce plasma persistence. However, their effect on tissue uptake of HES has not been investigated in human subjects.

Objective

Our objective was to test the hypothesis that lower molecular weight and substitution decrease tissue uptake of HES.

Data sources

Computer searches were performed of MEDLINE; EMBASE; the Cochrane Library; meeting abstract databases in surgery, anaesthesiology and intensive care; ClinicalTrials.gov; and Google. Supplementary sources were reference lists and electronic tables of journal contents. No time period or language restrictions were imposed.

Study Selection

Clinical studies were eligible for inclusion in the meta-analysis, if data were reported both for cumulative urinary excretion of HES over 24 hours after infusion and for plasma HES concentration at 24 hours.

Data Extraction

Data were extracted on 24-hour urinary excretion of HES, 24-hour HES plasma concentration, plasma volume, HES molecular weight and substitution, study design, type and demographics of subjects, indication for fluid infusion, and HES infusion regimen. Tissue uptake of HES was computed as the difference between the infused dose and the sum of urinary excretion and residual plasma HES at 24 hours.

Data Synthesis

Twenty-five clinical studies totalling 287 subjects were included. Tissue uptake of low-molecular-weight HES (≤200 kD) was 42.3% (95% confidence interval [CI] 39.6, 45.0) compared with 24.6% (CI 17.8, 31.4) for high-molecular-weight HES (p<0.001). Similarly, tissue uptake of lower-substitution HES (≤0.5) was 42.4% (CI 39.5, 45.3) versus 26.6% (CI 19.6, 33.6) for higher-substitution HES (p<0.001). Among the three most often investigated single HES solutions, tissue uptake of 130/0.4 (42.6%; CI 35.0, 50.2) and HES 200/0.5 (43.3%; CI 39.4, 47.2) closely coincided, whereas uptake of HES 450/0.7 (22.2%; CI 14.8, 29.6) was lower (p = 0.001 and p<0.001, respectively).

Conclusions

This meta-analysis did not support the hypothesis that lower molecular weight and substitution decrease tissue uptake of HES. Further clinical studies of HES tissue uptake are needed.

Schortgen F, Deye N, Brochard L. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 2004 Dec; 30(12): 2222–9PubMedCrossRef

Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004 May; 139(5): 552–63PubMedCrossRef

Bork K. Pruritus precipitated by hydroxyethyl starch: a review. Br J Dermatol 2005 Jan; 152(1): 3–12PubMedCrossRef

Pfeifer U, Kult J, Förster H. Ascites als Komplikation hepatischer Speicherung von Hydroxyethylstärke (HES) bei Langzeitdialyse. Klin Wochenschr 1984 Sep 17; 62(18): 862–6PubMedCrossRef

Schmidt-Hieber M, Loddenkemper C, Schwartz S, et al. Hydrops lysosomalis generalisatus — an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006 Jul; 77(1): 83–5PubMedCrossRef

Westphal M, James MF, Kozek-Langenecker S, et al. Hydroxyethyl starches: different products — different effects. Anesthesiology 2009 Jun 8; 111(1): 187–202PubMedCrossRef

Ferber HP, Nitsch E, Förster H. Studies on hydroxyethyl starch: part II. Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers. Arzneimittelforschung 1985; 35(3): 615–22PubMed

Treib J, Haass A, Pindur G, et al. HES 200/0.5 is not HES 200/0.5: influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74(6): 1452–6PubMed

Thompson WL, Fukushima T, Rutherford RB, et al. Intravascular persistence, tissue storage, and excretion of hydroxyethyl starch. Surg Gynecol Obstet 1970 Nov; 131(5): 965–72PubMed

10.

Lindblad G, Falk J. Konzentrationsverlauf von Hydroxyäthylstärke und Dextran in Serum und Lebergewebe von Kaninchen und die histopathologischen Folgen der Speicherung von Hydroxyäthylstärke. Infusionstherapie 1976; 3(5): 301–3

11.

Paulini K, Sonntag W. Veränderungen des RHS der Ratte nach parenteraler Gabe von Dextran (Mw 40000) und Hydroxyäthylstärke (Mw 40000): Chemische, licht- und elektronenmikroskopische Untersuchungen. Infusionstherapie 1976; 3(5): 294–9

12.

Jesch F, Hübner G, Zumtobel V, et al. Hydroxyäthylstärke (HÄS 450/0,7) in Plasma und Leber: Konzentrationsverlauf und histologische Veränderungen beim Menschen. Infusionsther Klin Ernahr 1979 Apr; 6(2): 112–7PubMed

13.

Förster H, Wicarkzyk C, Dudziak R. Bestimmung der Plasmaelimination von Hydroxyaethylstärke und von Dextran mittels verbesserter analytischer Methodik. Infusionstherapie 1981 Apr; 2(2): 88–94

14.

Jungheinrich C, Scharpf R, Wargenau M, et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500mL) in mild-to-severe renal impairment. Anesth Analg 2002 Sep; 95(3): 544–51PubMed

15.

Waitzinger J, Bepperling F, Pabst G, et al. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003; 4(3): 149–57PubMedCrossRef

16.

Kalhorn TF, Yacobi A, Sum CY. Biliary excretion of hydroxyethyl starch in man. Biomed Mass Spectrom 1984 Apr; 11(4): 164–6PubMedCrossRef

17.

Lenz K, Schimetta W, Pölz W, et al. Intestinal elimination of hydroxyethyl starch? Intensive Care Med 2000 Jun; 26(6): 733–9PubMedCrossRef

18.

Sirtl C, Laubenthal H, Zumtobel V, et al. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth 1999 Apr; 82(4): 510–5PubMedCrossRef

19.

Ständer S, Szépfalusi Z, Bohle B, et al. Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical long-term study. Cell Tissue Res 2001 May; 304(2): 261–9PubMedCrossRef

20.

Nohé B, Burchard M, Zanke C, et al. Endothelial accumulation of hydroxyethyl starch and functional consequences on leukocyte-endothelial interactions. Eur Surg Res 2002 Sep–Oct; 34(5): 364–72PubMedCrossRef

21.

Asskali F, Förster H. Zur Kumulation unterschiedlich substituierter Hydroxyethylstärke (HES) nach repetitiver Infusion bei gesunden Versuchspersonen. Anästhesiol Intensivmed Notfallmed Schmerzther 1999 Sep; 34(9): 537–41PubMedCrossRef

22.

Ballinger 2nd WF, Murray GF, Morse EE. Preliminary report on the use of hydroxyethyl starch solution in man. J Surg Res 1966 Apr; 6(4): 180–3PubMedCrossRef

23.

Lee Jr WH, Cooper N, Weidner Jr MG, et al. Clinical evaluation of a new plasma expander hydroxyethyl starch. J Trauma 1968 May; 8(3): 381–93PubMedCrossRef

24.

Solanke TF. Clinical trial of 6 per cent hydroxyethyl starch (a new plasma expander). Br Med J 1968 Sep 28; 3(621): 783–5PubMedCrossRef

25.

Metcalf W, Papadopoulos A, Tufaro R, et al. A clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet 1970 Aug; 131(2): 255–67PubMed

26.

Mishler JM, Borberg H, Emerson PM, et al. Hydroxyethyl starch: an agent for hypovolemic shock treatment. I: serum concentrations in normal volunteers following three consecutive daily infusions. J Surg Res 1977 Oct; 23(4): 239–45PubMedCrossRef

27.

Mishler JM, Borberg H, Emerson PM, et al. Hydroxyethyl starch: an agent for hypovolaemic schock treatment. II: urinary excretion in normal volunteers following three consecutive daily infusions. Br J Clin Pharmacol 1977 Oct; 4(5): 591–5PubMedCrossRef

28.

Mishler IV JM, Parry ES, Petrie A, et al. Plasma clearance and renal excretion of erythrocyte cryoprotectant hydroxyethylated amylopectin. Br J Haematol 1978 Oct; 40(2): 231–7PubMedCrossRef

29.

Mishler JM, Parry ES, Sutherland BA, et al. A clinical study of low molecular weight-hydroxyethyl starch, a new plasma expander. Br J Clin Pharmacol 1979 Jun; 7(6): 619–22PubMedCrossRef

30.

Mishler JM, Ricketts CR, Parkhouse EJ, et al. Catabolism of low-molecular-weight hydroxyethylated amylopectin in man: I. Changes in the circulating molecular composition. J Lab Clin Med 1979 Dec; 94(6): 841–7PubMed

31.

Mishler IV JM. Pharmakokinetik mittelmolekularer Hydroxyäthylstärke (HÄS 200/0,5). Infusionsther Klin Ernahr 1980 Apr; 7(2): 96–102PubMed

32.

Mishler JM, Ricketts CR, Parkhouse EJ, et al. The catabolism of low molecular weight-hydroxyethylated amylopectin in man: II. Changes in the urinary molecular profiles. Int J Clin Pharmacol Ther Toxicol 1980 Jan; 18(1): 5–9PubMed

33.

Mishler JM, Ricketts CR, Parkhouse EJ. Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man. J Clin Pathol 1981 Apr; 34(4): 361–5PubMedCrossRef

34.

Köhler H, Zschiedrich H, Linfante A, et al. Die Elimination von Hydroxyäthylstärke 200/0,5, Dextran 40 und Oxypolygelatine. Klin Wochenschr 1982 Mar; 60(6): 293–301PubMedCrossRef

35.

Köhler H, Zschiedrich H, Clasen R, et al. Blutvolumen, kolloidosmotischer Druck und Nierenfunktion von Probanden nach Infusion mittelmolekularer 10% Hydroxyäthylstärke 200/0,5 und 10% Dextran 40. Anaesthesist 1982 Feb; 31(2): 61–7PubMed

36.

Yacobi A, Stoll RG, Sum CY, et al. Pharmacokinetics of hydroxyethyl starch in normal subjects. J Clin Pharmacol 1982 Apr; 22(4): 206–12PubMedCrossRef

37.

Korttila K, Gröhn P, Gordin A, et al. Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 1984 Jul; 24(7): 273–82PubMedCrossRef

38.

Waitzinger J, Bepperling F, Pabst G, et al. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Investig 1998; 16(2): 151–60PubMedCrossRef

39.

Asskali F, Warnken U, Förster H. Acetylstärke als Volumenersatz, eine mögliche Alternative zu HES. Dtsch Med Wochenschr 2001 Jan 5; 126(1–2): 1–6PubMedCrossRef

40.

Förster H, Lehmann G, Asskali F. Das in vivo mittlere Molekular-gewicht und die Nierenschwelle von Hydroxyethylstärke am Beispiel mittelsubstituierter HES (HES 70/0,5). Anästhesiol Intensivmed Notfallmed Schmerzther 2001 Jan; 36(1): 31–7PubMedCrossRef

41.

Wilkes NJ, Woolf RL, Powanda MC, et al. Hydroxyethyl starch in balanced electrolyte solution (Hextend®) — pharmacokinetic and pharmacodynamic profiles in healthy volunteers. Anesth Analg 2002 Mar; 94(3): 538–44PubMedCrossRef

42.

Lehmann G, Asskali F, Förster H. Pharmacokinetics of hydroxyethyl starch (70/0.5) following repeated infusions. Transfus Med Hemother 2003 Mar; 30(2): 72–7CrossRef

43.

Lesch A. Hydroxyethylstärke (HES) im Urin nach Mehrfachinfusion von HES (450/0,7): Physiko-chemische Veränderungen der Substanzcharakteristika einer hochsubstituierten, hochmolekularen HES [dissertation]. Frankfurt: Johann Wolfgang Goethe-Universitä, 2003

44.

Lehmann GB, Asskali F, Boll M, et al. HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth 2007 May; 98(5): 635–44PubMedCrossRef

45.

Lehmann G, Marx G, Förster H. Bioequivalence comparison between hydroxyethyl starch 130/0.42/6:1 and hydroxyethyl starch 130/0.4/9:1. Drugs R D 2007; 8(4): 229–40PubMedCrossRef

46.

Bogan RK, Gale GR, Walton RP. Fate of ¹⁴C-labeled hydroxyethyl starch in animals. Toxicol Appl Pharmacol 1969; 15(1): 206–11CrossRef

47.

Eisenbach C, Schönfeld AH, Vogt N, et al. Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution. Intensive Care Med 2007 Jun 7; 33(9): 1637–44PubMedCrossRef

48.

Lukasewitz P, Kroh U, Löwenstein O, et al. Quantitative Untersuchungen zur Gewebsspeicherung von mittelmolekularer Hydroxyethylstärke 200/0,5 bei Patienten mit Multiorganversagen. J Anaesth Intensivbeh 1998; 3(3): 42–6

49.

Cittanova ML, Leblanc I, Legendre C, et al. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996 Dec 14; 348(9042): 1620–2PubMedCrossRef

50.

de Labarthe A, Jacobs F, Blot F, et al. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 2001 Oct 1; 111(5): 417–8PubMedCrossRef

51.

Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008 Mar; 51(3): 491–503PubMedCrossRef

52.

Kiehl P, Metze D, Kresse H, et al. Decreased activity of acid α-glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch. Br J Dermatol 1998 Apr; 138(4): 672–7PubMedCrossRef

53.

Metze D, Reimann S, Szepfalusi Z, et al. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997 Apr; 136(4): 553–9PubMedCrossRef

54.

Christidis C, Mal F, Ramos J, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001 Dec; 35(6): 726–32PubMedCrossRef

55.

Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 2001 Aug; 72(2): 527–33PubMedCrossRef

56.

Wiedermann CJ. Hydroxyethyl starch - can the safety problems be ignored? Wien Klin Wochenschr 2004 Sep 30; 116(17-18): 583–94PubMedCrossRef

57.

Davidson IJ. Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006 Sep; 23(9): 721–38PubMedCrossRef

58.

Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008 Jan 24; 8(1): 1–8PubMedCrossRef

59.

Zarychanski R, Turgeon AF, Fergusson DA, et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 2009; 3(4): E196–209PubMed

60.

Dart AB, Mutter TC, Ruth CA, et al. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010; (1): CD007594PubMed

Title: Effect of Molecular Weight and Substitution on Tissue Uptake of Hydroxyethyl Starch
A Meta-Analysis of Clinical Studies
Authors: Romuald Bellmann
Clemens Feistritzer
Professor Christian J. Wiedermann
Publication date: 01-04-2012
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 4/2012
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/11594700-000000000-00000

At a glance: The STEP trials

Springer Medicine

Effect of Molecular Weight and Substitution on Tissue Uptake of Hydroxyethyl Starch

A Meta-Analysis of Clinical Studies

Abstract

Background

Objective

Data sources

Study Selection

Data Extraction

Data Synthesis

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Data sources

Study Selection

Data Extraction

Data Synthesis

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials

Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing

Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics